{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:22:21Z","timestamp":1788985341883,"version":"build-2803163510"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Deucravacitinib is a novel oral selective tyrosine kinase 2 inhibitor used to treat plaque psoriasis. The most common cutaneous adverse effects are acne and folliculitis. We present a series of seven patients with prototypical papulopustular rosacea (PPR) following commencement of deucravacitinib. Although most of our patients demonstrated improvement in psoriasis on deucravacitinib, all seven patients discontinued therapy because of the severity and impact of PPR. Rosacea can be a severe adverse effect of deucravacitinib, impacting tolerability and influencing future treatment options.<\/jats:p>","DOI":"10.1093\/ced\/llaf418","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T11:29:42Z","timestamp":1757935782000},"page":"2482-2485","source":"Crossref","is-referenced-by-count":1,"title":["TYK-ed off by rosacea: an Australian case series of rosacea associated with deucravacitinib"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2288-3355","authenticated-orcid":false,"given":"Zachary","family":"Warren","sequence":"first","affiliation":[{"name":"Department of Dermatology , Monash Health, Melbourne, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8234-2682","authenticated-orcid":false,"given":"Chloe","family":"West","sequence":"additional","affiliation":[{"name":"Vital Dermatology, Adelaide, SA ,","place":["Australia"]},{"name":"Department of Dermatology, Flinders Medical Centre , Adelaide, SA ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Sander","sequence":"additional","affiliation":[{"name":"Central Dermatology Clinic , Maroochydore, QLD ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3976-1432","authenticated-orcid":false,"given":"Francis Yi Xing","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Dermatology , Monash Health, Melbourne, VIC ,","place":["Australia"]},{"name":"Department of Dermatology, Skin Health Institute , Melbourne, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"2025112512423665700_llaf418-B1","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/bjd\/ljae014","article-title":"Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials","volume":"190","author":"Lebwohl","year":"2024","journal-title":"Br J Dermatol"},{"key":"2025112512423665700_llaf418-B2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2025112512423665700_llaf418-B3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program for Evaluation of a TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2025112512423665700_llaf418-B4","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025112512423665700_llaf418-B5","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"},{"key":"2025112512423665700_llaf418-B6","first-page":"1269","article-title":"Upadacitinib induced erythema, papules and pustules \u2013 Is it really acne or is it rosacea?","volume":"22","author":"H\u00f6lzle","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"2025112512423665700_llaf418-B7","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jamadermatol.2023.3830","article-title":"Janus kinase inhibitors and adverse events of acne: a systematic review and meta-analysis","volume":"159","author":"Martinez","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"402","key":"2025112512423665700_llaf418-B8","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2025112512423665700_llaf418-B9","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/j.immuni.2022.08.001","article-title":"Innate type 2 immunity controls hair follicle commensalism by Demodex mites","volume":"55","author":"Ricardo-Gonzalez","year":"2022","journal-title":"Immunity"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf418\/64295537\/llaf418.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/12\/2482\/64295537\/llaf418.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/12\/2482\/64295537\/llaf418.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T17:42:42Z","timestamp":1764092562000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/12\/2482\/8256486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":9,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,9,17]]},"published-print":{"date-parts":[[2025,11,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf418","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,9,17]]}}}